The US FDA intends to adopt a more systematic approach to advice and data reviews on the blood pressure effects of new drugs that is modeled after its evaluation of pro-arrhythmic effects.
Norman Stockbridge, director of FDA’s Division of Cardiovascular and Renal Products, said the agency is looking to standardize its approach...